CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(12): 1273-1277
DOI: 10.1055/a-1019-7720
GebFra Science
Statement/Stellungnahme
Georg Thieme Verlag KG Stuttgart · New York

Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019

Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)Article in several languages: English | deutsch
Günter Emons
1  Universitätsmedizin Göttingen, Göttingen, Germany
,
Clemens Tempfer
2  Ruhr Universität Bochum, Bochum, Germany
,
Marco Johannes Battista
3  Universitätsklinik Mainz, Mainz, Germany
,
Alexander Mustea
4  Universitätsklinikum Bonn, Bonn, Germany
,
Dirk Vordermark
5  Universitätsklinik Halle (Saale), Halle (Saale), Germany
,
for the Uterus Commission of the AGO› Author Affiliations
Further Information

Publication History

received 25 September 2019

accepted 26 September 2019

Publication Date:
11 December 2019 (online)

Abstract

The role of adjuvant radiotherapy and/or chemotherapy in the primary treatment of endometrial cancer with a high risk of recurrence has still not been conclusively determined. The results of 3 large randomized controlled studies on different aspects of this issue have been published in full in recent months, and the relevant results are analyzed here.